Federal Cannabis Legal Status Remains Contradictory in 2026

Federal Prohibition Persists Under Controlled Substances Act

Cannabis remains a Schedule I controlled substance under 21 U.S.C. § 812, the same classification as heroin and LSD. The Drug Enforcement Administration hasn't completed its proposed rescheduling to Schedule III, a process initiated in August 2023 following a Department of Health and Human Services recommendation. No final rule has been published in the Federal Register.

Schedule I means the federal government considers cannabis to have no accepted medical use and a high potential for abuse. This classification has remained unchanged since the Controlled Substances Act took effect in 1970.

State-Legal Markets Operate in Federal Gray Zone

Thirty-eight states have enacted medical cannabis programs, and 24 states permit adult-use sales, but these markets exist without federal authorization. State-licensed dispensaries, cultivators, and processors operate under the assumption that federal prosecutors will exercise enforcement discretion—a policy framework with no statutory foundation.

The Cole Memorandum formalized DOJ non-enforcement priorities in 2013. It was rescinded in 2018. No replacement guidance has been issued. Federal prosecution of state-compliant operators remains legally permissible.

Banking Access Blocked by Federal Money-Laundering Statutes

Most federally insured banks refuse cannabis accounts because depositing proceeds from Schedule I drug sales constitutes money laundering under 18 U.S.C. § 1956. The SAFE Banking Act, which would create a federal safe harbor for cannabis banking, has passed the House seven times since 2019 but has never advanced to a Senate floor vote.

Operators rely on state-chartered credit unions, cash management services, or uninsured depositories. Cash-intensive operations create security risks and complicate tax compliance.

Internal Revenue Code 280E Blocks Standard Deductions

Cannabis businesses can't deduct ordinary expenses under 26 U.S.C. § 280E, which prohibits deductions for businesses trafficking in Schedule I or II substances. Operators may deduct cost of goods sold but not payroll, rent, marketing, or compliance expenses. Effective tax rates routinely exceed 70 percent of gross profit.

Rescheduling to Schedule III would eliminate 280E liability, but only if the DEA finalizes the proposed rule. The administrative record for the rescheduling docket closed in December 2024. No hearing date has been set.

Interstate Commerce Prohibited Despite State Reciprocity

No cannabis product may cross state lines, even between two adult-use states, because interstate transport of a Schedule I substance violates the Controlled Substances Act. Oregon and California have explored interstate-commerce compacts, but federal law preempts such agreements.

Every state market operates as a closed loop. Cultivators in Oregon can't ship surplus inventory to undersupplied markets in New York. This fragmentation drives inefficiency and limits economies of scale.

Rescheduling Proposal Stalled in Administrative Review

The DEA's proposed rule to reschedule cannabis to Schedule III was published for public comment in May 2024, but no final rule has been issued. The Administrative Procedure Act requires the agency to review submitted comments, hold a hearing if contested facts exist, and publish a final rule with a reasoned basis.

More than 43,000 comments were submitted during the 60-day comment period. Industry groups, state attorneys general, and medical organizations filed detailed technical objections. The DEA hasn't announced a timeline for resolution.

What Comes Next for Federal Cannabis Policy

The legal status of cannabis in the United States will remain contradictory until Congress passes comprehensive reform or the DEA completes rescheduling. Legislative vehicles under consideration include the SAFER Banking Act, the CAOA (Cannabis Administration and Opportunity Act), and standalone descheduling bills.

For background on the federal-state legal conflict and its operational implications, see the CannIntel topic hub on federal cannabis legality. We'll be watching whether the DEA schedules an administrative hearing or bypasses contested issues and issues a final rule. That decision is expected by the end of the third quarter.